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1. Introduction 
Progressive loss of renal allograft function after the first year of kidney transplant is often 
referred to as chronic rejection, transplant nephropathy, transplant glomerulopathy or 
chronic allograft nephropathy (CAN) and the use of these terms is often interchangeable. 
Clinically, it is usually diagnosed by a slowly rising serum creatinine level, increasing 
proteinuria and worsening hypertension (Zhang et al., 2004). CAN is the second most 
common cause of graft loss after the leading cause, death with a functioning graft (DWFG) 
(Zhang et al., 2004). According to estimates, 25-30% of patients currently awaiting kidney 
transplant have received a transplant before. 
With the widespread usage of induction agents and the advancements in 
immunosuppressive medications, the first year outcomes after kidney transplant have 
shown steady improvement. In the United States, the incidence of acute rejection (AR) in the 
first year is below 10% (United States Renal Data System [USRDS]) while the unadjusted 
graft survival is 96%, 92% and 85% for living, deceased and extended criteria deceased 
donors respectively (Organ Procurement and Transplant Network/Scientific Registry of 
Transplant Recipients [OPTN/SRTR], 2008).  
In the long term though, the survival of grafts has shown very little improvement over the past 
decade. The 5 year graft survival is reported at 81%, 71% and 55% for living, deceased and 
extended criteria deceased donors in the time interval of year 2000-2005. This, in comparison, 
is hardly different from the 79%, 68% and 51% reported in the interval of 1994-1999 
(OPTN/SRTR, 2008). The median graft survival years for all kidney transplants, according to a 
report published in 2004 has changed little when comparing transplants performed in the 
years 1988 through 1995, ranging between 7.5 to 8.0 years. (Meier-Kriesche et al, 2004) 
An overall shortage of organs and the high cost of providing any form of renal replacement 
therapy inclusive of a kidney transplant, calls for attention into making efforts for kidney 
transplants to last longer. This would entail looking into the pathological processes that 
result in the eventual failure of grafts, delineating as far as possible one process from the 
other, and examining immunological and non-immunological determinants that may be 
targeted with the eventual goal of adopting strategies that may help in prolonging the 
survival of renal allografts (Zhang et al, 2004). The non-immunological factors may include 
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poor graft quality, ischemia and reperfusion injury, delayed graft function, recurrent or de 
novo kidney disease, hypertension, diabetes, obstruction, infection, renal artery stenosis and 
calcineurin inhibitor toxicity. It has been recently suggested that the autoimmunity may also 
contribute to the post-transplant allograft injury (Dinavahi et al., 2011; Porcheray et al., 2010; 
Vendrame et al.,2010). Here, we will focus our discussion on the allo-immunological injury, 
as this mechanism has been well established and its importance has been increasingly 
recognized in the pathogenesis of CAN.  
2. Pathological classification  
The 8th Banff Conference on Allograft Pathology, held in 2005 (Solez et al, 2007) focused on 
removing the term CAN as a pathological entity. This term was first used in 1991 when it 
replaced the term ‘chronic rejection’. While it was successful in removing the notion that an 
immunologically mediated mechanism was in all instances the reason for the graft to slowly 
deteriorate, its use as a generic term came in the way of ascertaining a specific diagnosis and 
identification of the actual pathological process at play.  
While the pathological findings of ‘interstitial fibrosis and tubular atrophy’ (IF/TA) are 
common in most instances of chronic allograft injury, other features can sometimes point 
towards the actual disease process. For example, arterial fibrointimal thickening with 
duplication of internal elastica (fibroelastosis), arteriolar and small artery hyalinosis, 
glomerulosclerosis, along with IF/TA can be a manifestation of chronic hypertension (Olson 
et al, 1998); hyaline arteriolar changes, sometimes with peripheral hyaline nodules, and 
IF/TA either in ‘striped’ ischemic or diffuse form can be secondary to calcineurin inhibitor 
(CNI) toxicity (Morozumi et al, 2004, Basauschina et al, 2004 and Mihatsch et al, 1995); 
IF/TA with relative glomerular sparing, dilated tubules, atubular glomeruli and 
intratubular Tamm–Horsfall protein casts with extravasation into the interstitium may 
suggest chronic obstruction (Klahr et al, 2003); IF/TA with chronic inflammation, 
intranuclear inclusions highlighted on immunostaining for the SV40 large T antigen can be 
due to BK virus infection (Drachenberg et al, 2005), a polyoma virus that may infect the 
tubular cells in immune suppressed patients. In other instances, recurrent or de novo 
vascular or glomerular diseases may lead to glomerulosclerosis along with IF/TA. 
This leads to a new category of “interstitial fibrosis and tubular atrophy, no evidence of any 
specific etiology” to replace “CAN”. There is further sub-categorization within the category 
of “IF/TA, no evidence of any specific etiology” and this is based on amount of interstitial 
fibrosis, and the degree of atrophy and loss of tubules. It is described as mild (Grade I), 
moderate (Grade II) and severe (Grade III) determined by <25%, 25-50% and >50% of the 
cortical area involved respectively (Salez et al, 2007). The pitfall to this classification is that 
the degree of IF/TA in a renal graft is yet to be shown to correlate with the prognosis and 
overall graft survival. This is therefore an area where protocol biopsies done at previously 
determined time intervals, and the correlation of these results with graft survival in the long 
term, will provide invaluable prognostic information.  
In the same revision of the Banff criteria, there was also the introduction of the subcategories 
of ‘chronic active antibody mediated rejection’ and ‘chronic active T-cell mediated rejection’ 
within the categories of antibody mediated rejection (AMR) and T-cell mediated rejection 
respectively. These were introduced to highlight the features of arterial and capillary 
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changes, believed to be pathognomonic of an immunologically mediated chronic allograft 
injury which would also have IF/TA, in other words identifying true chronic rejection. The 
need for introducing the subcategory of chronic antibody mediated rejection (CAMR) was 
based on the abundantly available literature that highlighted the presence of complement 
fragments (C4d) positivity (explained in more detail in Role of B cells and DSA) and the 
presence of anti-HLA antibodies in transplant patients correlating with the chronic failing of 
the allografts. When these are seen in the presence of pathological changes specific to an 
active process of AMR taking place, that subset of patients could be safely assumed to be 
undergoing an immunologically mediated, in specific humorally mediated reaction. The 
diagnostic criteria therefore for ‘CAMR’ are as follows; 
Morphological features of duplication or ‘double contours’ in glomerular basement 
membranes, and/or peri-tubular capillary basement membrane multi-layering (PTCBMML) 
and/or IF/TA with or without PTC loss, and/or fibrous intimal thickening in arteries 
without duplication of the internal elastica 
1. C4d deposition in the peri-tubular capillaries (PTC)  
2. The presence of donor specific antibodies (DSA)  
The pathological significance of these findings and their role in causing deterioration in 
graft function will be highlighted in the section “Role of B-cells and DSA” below. Transplant 
glomerulopathy of membrano-proliferative glomerular nephritis (MPGN) pattern should be 
distinguished from the immune complex-mediated MPGN that is frequently associated with 
hepatitis C infection or due to recurrent or de novo glomerular disease. They appear similar 
(MPGN) on light microscopy, but their distinction can be made by electron microscopy, as 
transplant glomerulopathy does not have immune-complex deposits on the glomerular 
basement membrane.  
‘Chronic active T-cell mediated rejection’ is described as a subcategory of “T-cell mediated 
rejection” and it denotes the presence of chronic allograft arteriopathy with arterial intimal 
fibrosis along with mononuclear cell infiltration and fibrosis and the formation of neo-
intima. These changes and their role will also be described in more detail in the section 
“Role of T-cell” below.  
3. Role of T cells  
The introduction of an “allograft” into an immunocompetent individual would typically 
result in a process of recognizing the graft tissue as foreign “allorecognition” and the 
initiation of what is known as an “alloresponse”, invariably resulting in tissue inflammation, 
architectural distortion and infiltration by T-cells that are responsive to the graft resulting in 
loss of function and eventual failure of the graft, a process we call acute cellular rejection. 
This occurs after a number of steps taking place at the molecular and cellular level, steps 
that have been recognized and become the target of therapy in order to prevent rejection.  
Allorecognition can occur by three well-described mechanisms referred to as direct, indirect 
and the semi direct pathways. (Safinia et al, 2010). In the direct pathway recipient T cells 
recognize intact allogeneic major histocompatibility complex or MHC-peptide complexes 
expressed by foreign cells, while in the indirect pathway T cells recognize peptides derived 
from allogeneic MHC proteins presented by antigen-presenting cell and finally the semi 
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direct pathway where recipient dendritic cells acquire intact allogeneic MHC–peptide 
complexes from donor cells and present them to recipient T cells. (Harrera et al., 2004; 
Lechlar and Batchelar, 1982; Warrens et al., 1994). In the context of transplantation, while the 
direct and the indirect pathways are well recognized and understood, the semi-direct 
pathway is not known to be of clinical importance in allograft rejection. (Figure 1)  
 
Fig. 1. Mechanism of antigen presentation in the direct and indirect pathways. 
As far as the direct pathway is concerned, if the immunological milieu is left unaltered, a 
strong and effective alloresponse would follow primarily due to the very high number of 
recipient T-cells that will recognize the transplant tissue as foreign. Due to the nature of this 
mechanism, this pathway is of primary importance in the immediate post transplant period. 
T-cell depletion using various immunosuppressive regimens, including induction protocols, 
severely compromises this process. Another phenomenon observed is depletion of donor 
derived dendritic cells through apoptosis and elimination by recipient immune reactivity. 
This is also accompanied by a decline in the number of recipient T cells with direct 
antidonor allospecificity with time, most pronounced in the CD4+ CD45RO+ (memory) 
subset (Hornick et al, 1998). However, this decline in direct pathway responses with time is 
as pronounced in patients with chronic rejection as in those with stable graft function and 
this supports the view that the direct pathway of allorecognition is of little importance in the 
context of chronic graft failure. 
As the direct pathway declines with time, recipient dendritic and other antigen presenting 
cells travel through the graft, picking up soluble MHC alloantigens or antigens derived from 
donor cells and present them to T-cells activating CD4 + and CD 8+ cells (the indirect 
pathway) (Auchincloss et al. , 1993; Kievits et al.,1991). The predominant antigen 
presentation is done through MHC-Class II cells which have an affinity towards the CD4+ 
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T-cell subtype. The indirect alloresponse, while less rapid compared with the direct 
pathway, dominates reactivity to transplanted antigens in the long term. This is the main 
reason why, despite tolerance afforded by the direct pathway, immune suppression is 
required for as long as the graft remains viable. Any inflammation induces the expression of 
MHC class II molecules on endothelial and epithelial cells in the graft, conferring the ability 
to present antigen to CD4+ T cells (Bal et al., 1990).  
Clinically, the activity of T-cells in renal allografts is represented by cellular rejection. The 
diagnosis is made by detecting tubulitis, interstitial infiltration and edema, and sometimes 
intimal arteritis. A grade is assigned depending on the severity of these lesions. The 
inflammatory activity of T-cells results in renal injury resulting in architectural distortion of 
the renal parenchyma. The Banff Classification for T-cell mediated rejection along with 
histological description of each category and sub category is described below.  
3.1 T-cell mediated rejection 
Acute T-cell mediated rejection (Type/Grade) 
i. Significant tubular and interstitial infiltration (Figure 2) 
ii. Intimal arteritis (vascular rejection) (Figure 3) 
iii. Transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth 
muscle cells with accompanying lymphocytic inflammation (Figure 4) 
Chronic T-cell mediated rejection 
‘Chronic allograft arteriopathy’ (arterial intimal fibrosis with mononuclear cell 
infiltration in fibrosis, formation of neo-intima) 
 
Fig. 2. Infiltration of tubules and interstitium with T cells (Courtesy of Suzanne Meleg-Smith, 
MD.) 
4. Role of B cells and DSA 
Based on the principles of immunology, B cells are known to play vital roles, from antigen 
presentation, immune regulation, to their most characteristic role of differentiating into 
plasma cells that secrete antibodies. The secretion of antibodies and their role in the 
pathogenesis of CAN is what makes B cells of great clinical significance in the long term 
survival of the renal graft.  
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Fig. 3. Infiltration of arterial intima with T cells (Courtesy of Suzanne Meleg-Smith, MD.) 
 
Fig. 4. Fibrinoid necrosis of arterial wall and transmural infiltration of T cells (Courtesy of 
Suzanne Meleg-Smith, MD.) 
The association between graft dysfunction with antibodies produced against donor human 
leukocyte antigens (HLA) has long been recognized (Jeannet et al., 1970; Terasaki et al. 
2007). Their role in acute AMR is well defined and they have been popularly referred to as 
DSA. Their pathogenesis became evident with the discovery of deposition of complement 
fragments (C4d) along peritubular capillaries (PTC) in grafts of patients suffering from graft 
dysfunction and known to have circulating DSAs (Feuch et al., 1991). (Figure 5) 
In the context of CAN, arteriopathy or glomerulopathy in the transplanted kidney is also 
linked to C4d deposition in the PTCs and to DSAs (Mauiyyedi et al., 2001). The pattern of 
renal injury in these circumstances was further elaborated with the evidence that when 
chronic failure occurs in the renal allograft and circulating DSAs are present along with C4d 
deposition in the PTCs, capillaritis and basement membrane multi-lamination was seen 
(Regele et al.,2002). Other features described and attributed to this pathology include 
duplication of the glomerular basement membrane, mononuclear cell infiltration in the 
glomeruli and the PTCs along with loss of normal glomerular capillary endothelial 
fenestrations (Colvin et al. 2006). With well-described morphological features, along with 
association of DSA and C4d deposition, “chronic antibody mediated rejection (CAMR)” 
gained its place in the revision of the BANFF classification in 2005 (Solez et al., 2007). The 
presence of proteinuria is not pathognomonic but can be seen and graft function may seem 
quite stable for years. While the pathogenesis is strongly linked to circulating DSAs, prior 
sensitization or an episode of acute AMR are not essential pre-requisites. Instead, DSAs may 
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develop slowly and sub clinically, and eventually lead to the dysfunction of the allograft 
mediated by a slow inflammatory process.  
 
Fig. 5. Peritubular capillary deposition of C4d (right) in acute antibody mediated 
rejection.(Courtesy of Suzanne Meleg-Smith, MD.) 
With the development of a diagnostic criterion for CAMR, many of the pathological findings 
that had known to exist have been tied in and explain the underlying mechanism of renal 
injury. However, there are few caveats that still make the accurate recognition of this clinical 
entity challenging.  
One factor is that under certain circumstances, C4d deposition might not be seen. This could 
happen when the DSAs induce damage via a non-complement fixing mechanism (Collins et 
al., 2008). Further, in advanced stages of CAMR, when tubular atrophy has already 
developed, it may well be hard to recognize positive C4d staining. Conversely, when typical 
changes such as PTC multi-lamination are seen in the absence of C4d deposition and 
circulating DSA, there could be a possibility of another diagnosis such as chronic or 
resolving thrombotic micro-angiopathy or these lesions could be assumed to be from a 
previous episode of acute antibody-mediated injury.Laboratory studies have demonstrated 
that complement, although relied on in order to make a clinical diagnosis, is not necessary in 
the pathogenesis of CAMR. Induction of DSAs that are non-complement fixing can have the 
same pathological changes as DSA that fix complement. Also, in animals that are selectively 
deficient in C3 (RAG1 -/-), introduction of complement fixing antibodies results in similar 
pathological changes and poor outcomes of the graft (Jin et al. 2005). What has been found 
to have a more pronounced role in the development of allograft arteriopathy characteristic 
of CAMR, is a host of changes in the endothelium brought about by the infiltration of 
natural killer (NK) cells that express FcγRIII, which is a receptor for the Fc (Fragment 
crystallizable) or the constant region of antibodies. Hence it is believed that in the 
pathogenesis of CAN mediated by circulating DSAs, NK cells have much more of a role 
than complement (Hirohasha et al., 2008).  
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Yet another phenomenon observed in the context of circulating antibodies is that sometimes, 
there may be no evidence of graft destruction at all, even with varying degree of C4d 
deposition. This process, termed accommodation, has been the focus of research in recent 
years, with a wealth of insight provided by transplantation of organs across the barrier of 
ABO incompatibility. Though anti-A or B isoagglutinin reappear after transplant, they can 
co-exist without precipitating rejection (Gonzalez-Strawinski et al., 2008). Interestingly, C4d 
deposition can be observed but, compatible with other observations, does not necessarily 
mean that CAMR is taking place. Understanding the mechanism by which the graft attains 
this ability to remain “non-reactive” despite the presence of antibodies circulating against it 
is of great interest as it can be therapeutically mimicked when DSAs are known to exist that 
would otherwise lead to an immunologically mediated rejection of the graft. 
Accommodated grafts have been found to have changes in the cells of the endothelium and 
that are believed to help in the adaptation to the presence of antibodies. These changes 
include increased expression of bcl-xL, (Salama et al. 2001), increased muc-1 expression 
(Park et al. 2003) and increase in the expression of indolamine-2,3-dioxygenase (Minnei et 
al., 2008) in the glomerular and PTC endothelium.  
In conclusion, CAMR occurs slowly, with the first step being the development of DSA, 
followed by an immunological reaction that may result in the deposition of C4d, the 
resultant development of visible pathological changes characteristic of CAMR and then 
eventual graft loss. The speed at which these events occur is variable and the challenge is 
not just limited to the difficulty in diagnosis, but also in terms of therapy. In the future, the 
main strategies to counteract the risk for CAMR will be focused on screening for the 
development of new DSA, following the titers of known DSAs and correlating them with 
the function of the transplanted kidney. Also, as we learn more about the adaptive 
capabilities that lead to accommodation, strategies will likely be developed to mimic them 
in vivo to prolong the renal graft survival. 
5. Acute and sub-acute rejection 
Many studies have pointed out that the long term outcomes of transplanted kidneys that 
underwent episodes of AR are inferior compared to those that did not. The long term 
outcomes are even worse if the episodes of rejection have been multiple or if the acute 
rejection occurs late, usually meaning more than 6 months after the transplant. The obvious 
correlation here is that many times, non-compliance with immunosuppressive medications 
would be a confounding factor. What is also an obvious factor is that each episode of 
rejection leaves the transplanted organ with progressively increasing amounts of interstitial 
fibrosis and tubular atrophy with a cumulative effect of functional decline, eventually 
resulting in organ failure.  
However, the incidence of AR has markedly declined, with the actual incidence within the 
first year being less than 10% (USRDS, 2008). This decrease has not translated into an 
improvement in the overall graft survival or the median survival time of renal allografts. An 
explanation to this phenomenon may be that even when there is no acute allograft 
dysfunction in terms of worsening creatinine clearance, proteinuria or hypertension, there is 
an ongoing inflammatory infiltration that leads to structural damage and eventual scarring 
of the renal parenchyma, termed as subclinical rejection. This entity is usually discovered by 
protocol biopsies, which are not performed in a cross-sectional manner. This means that an 
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inflammatory response, which is not very severe, but in most cases chronic does occur and 
over time results in graft loss. There has been a clear demonstration that subclinical rejection 
leads to an early development of CAN and graft loss particularly if there is coexisting 
interstitial fibrosis and tubular atrophy (Cosio et al, 2005; Nankivell et al., 2004, Moreso et 
al., 2006; Shishido et al., 2003; Veronese et al. 2004). It is also important to stress that while 
there may not be a significant functional deterioration at the time sub-clinical rejection is 
diagnosed, many times the actual injury as demonstrated by protocol biopsies may be of 
high grade. One study categorized the results of a cohort of protocol biopsies and revealed 
that 1 out of 3 of these cases has interstitial acute rejection Grade 1 and 2 out of 3 were 
classified as borderline changes (Nankivell et al., 2004). There has also been a repeated 
demonstration that the degree of infiltration seen in protocol biopsies revealing subclinical 
rejection has correlated to the degree of HLA incompatibility further proving that this 
infiltration is driven by an immunological phenomenon. There are instances when there is 
clear histological demonstration of infiltration in the renal parenchyma with no rise in 
serum creatinine implying that there is no functional decline. This further elaborates the 
unreliability and underestimation of renal dysfunction offered by measuring serum 
creatinine level (Kaplan et al., 2003; Levey et al., 1999).  
This raises the question of whether protocol biopsies should be performed on a regular 
interval. While some studies have demonstrated a clear benefit in terms of a decreased 
incidence of AR and lower serum creatinine at two years after the kidney transplant (Rush 
et al., 1998), there have been other studies that indicate that treatment of subclinical 
infiltration on the basis of a protocol biopsy may not have significant improvement in the 
long term and may further expose the patient to increased amounts of immunosuppression 
and further the risk of CNI toxicity. Therefore, with the currently existing data, most centers 
do not perform protocol biopsies on all patients; however, experts do recommend 
performing protocol biopsies on at least some of the patients that are considered high risk 
where an inflammatory infiltrate likely means a clinical rejection. If left untreated, it will 
likely result in an accelerated course towards CAN and the eventual loss of function of the 
allograft.  
6. Degree of HLA mismatch 
Three pairs of human leukocyte antigens (HLA) loci A, B and DR are traditionally used for 
organ allocation. They exist on chromosome 6 with both alleles inherited from either parent 
are co-expressed, resulting in any individual having 6 antigens. There is tremendous 
amount of variation in the actual antigen that is coded by each of these loci among 
individuals as this gene exhibits what is known as polymorphism. With advances in 
molecular biology more than 230 polymorphisms have been identified for HLA-A, more 
than 470 for HLA-B and more than 380 for HLA-DR. Their relevance stems from the fact that 
these antigens are expressed on the surface of all cells and are the major barrier to 
transplantation. Because of the way our immunological system is designed, the recognition 
of self versus foreign antigens is mediated through these HLA antigens. Hence when foreign 
tissue is introduced to the immune system of a host and it is recognized as foreign, it is due 
to lack of tolerance that the host has developed towards its own variety of HLA antigens. 
As these antigens are carried on fixed loci, their inheritance follows a Mendelian pattern, 
and a combination of HLA-A, B and DR is inherited by an individual from both parents. 
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Hence, when identical twins or siblings, who have the same HLA antigens donate to each 
other, the survival is superior compared to randomly matched cadaveric donors, with an 
intermediate level of graft survival seen when parents or genetically non-identical siblings 
donate where one of the haplotypes are matched. In population based programs, which rely 
predominantly on cadaveric donation, finding single or double haplotype match is 
obviously not very common. The goal is to find a donor and recipient combination that has 
zero to minimum mismatches, meaning the least amount of HLA antigens expressed on the 
surface of donor cells that are not present in the recipient. There has also been recognition of 
the fact that there are some HLA mismatches that are more significant than others, for 
example having a DR mismatch is now known to be much more detrimental to graft 
survival than having a mismatch of the A and B antigens (Coupel et al., 2003; Opelz 1985).  
In the earlier years of transplantation, having HLA mismatches led to a high incidence of 
early rejection and eventual graft failure. With the modern and more potent 
immunosuppressive agents used today, such episodes are rare in the first year. However, 
despite the immune suppression and the low incidence  of AR  in the first year, the long 
term survival of grafts from well matched (6 antigen match or zero mismatch) donors have a 
longer survival than from those who are not as well matched and according to recent 
analysis of the national database in the United States (OPTN/SRTR, 2008) this effect is seen 
in living donors and deceased donors of both extended and non-extended criteria. Despite 
the above stated evidence pointing towards better survival among well matched organ 
allocation, only 13% of the organs allocated in the US are well matched. (Takemoto et al., 
2000). The main reasons are that despite the large numbers of people on the waiting list, 
well matched organs are difficult to find. When they are found, the absolute match may be 
in a different part of the country. If organ allocation is done by HLA only, not considering 
geographical location, the cold-ischemia time increases as the organ is transported. As the 
cold-ischemia time increases, chances of delayed graft function increase and overall it 
negatively affects outcomes and costs. According to an analysis, the added advantage of a 
zero mismatch is lost once the cold-ischemia time exceeds 36 hours (Lee et al., 2000). 
Exposure to foreign antigens whether in the form of organ donation, blood transfusion and 
in the case of women, through child birth, leads to development of antibodies that are 
reactive towards these antigens, a process referred to as “sensitization”. A measure known 
as the Panel Reactive Antibodies (PRA) estimates the degree of sensitization that a potential 
recipient has and this reflects the likelihood of having difficulty finding an organ to which 
the recipient does not have preformed antibodies against. Pre-existing DSA or developing 
de-novo DSA in the post-transplant period predisposes the recipient to develop AMR. Even 
if there is no overt episode of AMR  clinically, the graft survival is still poor, which is 
explained by development of transplant glomerulopathy from CAMR.  
Strategies to prevent CAN due to HLA incompatibility include matching donors and 
recipients with minimal mismatches, cross matching to ensure that there is no DSA. If DSA 
are present, various desensitization protocols utilizing intravenous immunoglobulin and 
plasmapheresis can be used to decrease the likelihood of AMR. In the post transplant 
period, a watchful evaluation of kidney function with close monitoring of serum markers as 
well as urinalysis should be kept to recognize early development of AMR and CAMR. The 
threshold to evaluate renal dysfunction with kidney biopsy should be low in patients at 
increased risk of rejection due to HLA incompatibility. In the outset, patients who are likely 
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to be in need of kidney transplantation should be transfused with caution during their 
course of CKD as well as when they are on renal replacement therapy to keep sensitization 
at minimum.  
7. Gender 
Due to lack of the Y chromosome in women, antigens coded for by the Y chromosome are 
recognized as foreign when organ transplantation occurs from a male donor to a female 
recipient (McGee et al., 2010, 2011). While this does not manifest immunologically as 
strongly as HLA incompatibility, it does have an effect of having shorter graft survival when 
an organ is taken from a male donor and transplanted to a female recipient (McGee et al., 
2010). This effect is more strongly noted among bone marrow transplants, but is also present 
to some degree in solid organ transplants such as the kidney (Gratwohl et al., 2008). The 
decreased survival of male to female donation compared to female to male donation is seen 
despite the fact that in most instances a higher nephron mass of a male donor kidney is 
transplanted into a smaller body of a female recipient.  
8. Summary 
The significant improvement in the short-term graft survival has not transformed into a 
much better long-term graft survival. CAN is an important cause of graft loss and it 
represents a complex process culminating immunological and non-immunological injuries. 
The occurrences of overt acute rejections, either cellular, humoral or both, in the early stage 
driven by allo-immunity can have an important bearing on the long term immunological 
milieu that prevails and hence influences the graft survival. Sub-clinical rejection and/ or 
chronic rejection from inadequate immunosuppression are frequently undiagnosed and 
untreated. Persistent DSA or de novo development of DSA after kidney transplant is 
increasingly recognized as an independent and detrimental factor for transplant 
glomerulopathy. Other than allo-reactivity, there are emerging data suggesting that the pre-
existing or de novo developing autoimmunity, mediated by either auto-antibodies and/or 
autoreactive T cells, may also cause post-transplant allograft injury (Dinavahi et al., 2011; 
Porcheray et al., 2010; Vendrame et al.,2010). Therefore, to appropriately identify and 
address the actual disease process, knowledge of the ongoing pathogenesis is needed in 
order to improve the long-term graft survival. From allo-immunological standpoint, it may 
include optimizing HLA match, avoiding sensitization, timely detecting  and treating AR 
episodes, and maintaining adequate levels of immunosuppression to prevent the 
development of DSA, sub clinical rejection and chronic rejection of allografts. 
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